BR0206825A - Formulação de dispersão sólida de liberação modificada, multiparticulada, processo para a preparação da formulação, uso da mesma, tablete, e, métodos para o tratamento de uma doença cardiovascular, e, para o tratamento de câncer - Google Patents
Formulação de dispersão sólida de liberação modificada, multiparticulada, processo para a preparação da formulação, uso da mesma, tablete, e, métodos para o tratamento de uma doença cardiovascular, e, para o tratamento de câncerInfo
- Publication number
- BR0206825A BR0206825A BR0206825-7A BR0206825A BR0206825A BR 0206825 A BR0206825 A BR 0206825A BR 0206825 A BR0206825 A BR 0206825A BR 0206825 A BR0206825 A BR 0206825A
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- tableting
- preparing
- methods
- cardiovascular disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"FORMULAçãO DE DISPERSãO SóLIDA DE LIBERAçãO MODIFICADA, MULTIPARTICULADA, PROCESSO PARA A PREPARAçãO DA FORMULAçãO, USO DA MESMA, TABLETE, E, MéTODOS PARA O TRATAMENTO DE UMA DOENçA CARDIOVASCULAR, E PARA O TRATAMENTO DE CâNCER". A presente invenção é dirigida a uma formulação de dispersão sólida de liberação modificada e multiparticulada, compreendendo substância droga, tendo uma solubilidade em água de ou abaixo de 8 mg/ml em temperatura ambiente; um formador de matriz hidrofóbica, que é um lipídeo anfifílico não-intumescível e insolúvel em água, que é um excipiente solúvel em água fundível, em que a relação em peso de formador de matriz hidrofóbica/formador de matriz hidrofílica é <242>; e, o tamanho de partícula é menor do que 300 <109>m. São também reivindicados uma dosagem da mesma, bem como um processo para sua preparação e o uso da formulação e dosagem unitária.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100477A SE0100477D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
| SE0100478A SE0100478D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
| PCT/SE2002/000228 WO2002064121A1 (en) | 2001-02-13 | 2002-02-08 | Novel modified released formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0206825A true BR0206825A (pt) | 2004-02-25 |
Family
ID=26655389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0206825-7A BR0206825A (pt) | 2001-02-13 | 2002-02-08 | Formulação de dispersão sólida de liberação modificada, multiparticulada, processo para a preparação da formulação, uso da mesma, tablete, e, métodos para o tratamento de uma doença cardiovascular, e, para o tratamento de câncer |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20040067256A1 (pt) |
| EP (2) | EP1368006B1 (pt) |
| JP (2) | JP2004518708A (pt) |
| KR (1) | KR20040058103A (pt) |
| CN (2) | CN1491105A (pt) |
| AT (1) | ATE324871T1 (pt) |
| AU (1) | AU2002228579B2 (pt) |
| BR (1) | BR0206825A (pt) |
| CA (2) | CA2434835A1 (pt) |
| DE (1) | DE60211130T2 (pt) |
| DK (1) | DK1368006T3 (pt) |
| ES (1) | ES2261643T3 (pt) |
| HK (1) | HK1059740A1 (pt) |
| IL (1) | IL157075A0 (pt) |
| MX (1) | MXPA03007092A (pt) |
| NO (1) | NO20033564L (pt) |
| NZ (2) | NZ526993A (pt) |
| PT (1) | PT1368006E (pt) |
| WO (2) | WO2002064121A1 (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| MXPA05003283A (es) * | 2002-09-28 | 2005-11-23 | Johnson & Johnson | Composicion de polimero y formas de dosis que comprenden la misma. |
| SE0301904D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | Novel imidazopyridine compound II with therapeutic effect |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| BRPI0414046A (pt) * | 2003-08-29 | 2006-10-24 | Dynogen Pharmaceuticals Inc | método de tratamento de um distúrbio de motilidade gastrintestinal, de tratamento de "gerd", de "gerd" noturno, composição farmacêutica, kit que compreende um composto e método para aumentar a motilidade esofágica em um paciente |
| BRPI0417348A (pt) * | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| AU2004294813A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
| SE0303451D0 (sv) * | 2003-12-18 | 2003-12-18 | Astrazeneca Ab | New compounds |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| EP2001445B1 (en) * | 2006-03-16 | 2014-07-23 | Euro-Celtique S.A. | Pharmaceutical spheroids |
| EP3028743A3 (en) * | 2008-03-05 | 2017-01-25 | Vicus Therapeutics, LLC | Compositions for mucositis and oncology therapies |
| WO2011000126A1 (zh) * | 2009-06-29 | 2011-01-06 | Liu Yu | 脂溶性药物组合物、制备方法及其用途 |
| EP3296295A1 (en) | 2009-08-07 | 2018-03-21 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
| US20130165880A1 (en) | 2010-09-17 | 2013-06-27 | David T. Amos | Antimicrobial disposable absorbent articles |
| US20140037574A1 (en) * | 2010-11-26 | 2014-02-06 | Pius Sedowhe Fasinu | Pharmaceutical composition |
| US20130149383A1 (en) * | 2011-12-12 | 2013-06-13 | Cory Berkland | Sustained release particle formulations of guaifenesin |
| CA2859174C (en) * | 2011-12-12 | 2019-03-05 | Orbis Biosciences, Inc. | Sustained release particle formulations |
| EP3319595A4 (en) * | 2015-06-30 | 2019-04-03 | Kemin Industries, Inc. | ENCAPSULATED ACTIVE INGREDIENTS FOR REGULATED ENERGETIC RELEASE |
| US9889120B2 (en) | 2016-01-14 | 2018-02-13 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
| DE102017108054A1 (de) | 2017-04-13 | 2018-10-18 | Natura Werk Gebr. Hiller GmbH & Co. KG | Essbare Zusammensetzung zur Verdauungsförderung |
| JP2023509800A (ja) | 2020-01-10 | 2023-03-09 | コンシナンス セラピューティクス， インコーポレイテッド | 薬物の治療的組み合わせ及びそれらの使用方法 |
| WO2023184282A1 (en) * | 2022-03-30 | 2023-10-05 | Guizhou Sinorda Biomedicine Co., Ltd | X842 formulation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL248553A (pt) * | 1959-02-18 | |||
| NL194389C (nl) * | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
| US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
| US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
| US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
| US5405617A (en) * | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
| US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
| US5851555A (en) * | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
-
2002
- 2002-02-08 WO PCT/SE2002/000228 patent/WO2002064121A1/en active IP Right Grant
- 2002-02-08 WO PCT/SE2002/000227 patent/WO2002064118A1/en not_active Application Discontinuation
- 2002-02-08 AU AU2002228579A patent/AU2002228579B2/en not_active Ceased
- 2002-02-08 AT AT02710645T patent/ATE324871T1/de not_active IP Right Cessation
- 2002-02-08 PT PT02710645T patent/PT1368006E/pt unknown
- 2002-02-08 CN CNA028049063A patent/CN1491105A/zh active Pending
- 2002-02-08 IL IL15707502A patent/IL157075A0/xx unknown
- 2002-02-08 CA CA002434835A patent/CA2434835A1/en not_active Abandoned
- 2002-02-08 ES ES02710645T patent/ES2261643T3/es not_active Expired - Lifetime
- 2002-02-08 US US10/467,900 patent/US20040067256A1/en not_active Abandoned
- 2002-02-08 KR KR10-2003-7010577A patent/KR20040058103A/ko active IP Right Grant
- 2002-02-08 JP JP2002563914A patent/JP2004518708A/ja active Pending
- 2002-02-08 DE DE60211130T patent/DE60211130T2/de not_active Expired - Fee Related
- 2002-02-08 CN CNA028049144A patent/CN1491104A/zh active Pending
- 2002-02-08 US US10/467,723 patent/US20040067252A1/en not_active Abandoned
- 2002-02-08 NZ NZ526993A patent/NZ526993A/en unknown
- 2002-02-08 CA CA002434542A patent/CA2434542A1/en not_active Abandoned
- 2002-02-08 JP JP2002563916A patent/JP2004518709A/ja active Pending
- 2002-02-08 BR BR0206825-7A patent/BR0206825A/pt not_active IP Right Cessation
- 2002-02-08 NZ NZ526994A patent/NZ526994A/en unknown
- 2002-02-08 EP EP02710645A patent/EP1368006B1/en not_active Expired - Lifetime
- 2002-02-08 DK DK02710645T patent/DK1368006T3/da active
- 2002-02-08 MX MXPA03007092A patent/MXPA03007092A/es active IP Right Grant
- 2002-02-08 EP EP02711597A patent/EP1361868A1/en not_active Withdrawn
-
2003
- 2003-08-12 NO NO20033564A patent/NO20033564L/no not_active Application Discontinuation
-
2004
- 2004-04-15 HK HK04102657A patent/HK1059740A1/xx not_active IP Right Cessation
-
2007
- 2007-05-14 US US11/748,366 patent/US20080118560A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040067252A1 (en) | 2004-04-08 |
| KR20040058103A (ko) | 2004-07-03 |
| EP1368006B1 (en) | 2006-05-03 |
| ES2261643T3 (es) | 2006-11-16 |
| JP2004518708A (ja) | 2004-06-24 |
| EP1361868A1 (en) | 2003-11-19 |
| NZ526993A (en) | 2005-01-28 |
| DE60211130T2 (de) | 2006-11-30 |
| DE60211130D1 (de) | 2006-06-08 |
| EP1368006A1 (en) | 2003-12-10 |
| US20080118560A1 (en) | 2008-05-22 |
| US20040067256A1 (en) | 2004-04-08 |
| IL157075A0 (en) | 2004-02-08 |
| ATE324871T1 (de) | 2006-06-15 |
| AU2002228579B2 (en) | 2006-07-27 |
| CN1491104A (zh) | 2004-04-21 |
| MXPA03007092A (es) | 2003-11-18 |
| WO2002064121A1 (en) | 2002-08-22 |
| DK1368006T3 (da) | 2006-07-24 |
| NO20033564L (no) | 2003-10-02 |
| PT1368006E (pt) | 2006-08-31 |
| CA2434835A1 (en) | 2002-08-22 |
| HK1059740A1 (en) | 2004-07-16 |
| WO2002064118A1 (en) | 2002-08-22 |
| CN1491105A (zh) | 2004-04-21 |
| JP2004518709A (ja) | 2004-06-24 |
| CA2434542A1 (en) | 2002-08-22 |
| NZ526994A (en) | 2005-01-28 |
| NO20033564D0 (no) | 2003-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0206825A (pt) | Formulação de dispersão sólida de liberação modificada, multiparticulada, processo para a preparação da formulação, uso da mesma, tablete, e, métodos para o tratamento de uma doença cardiovascular, e, para o tratamento de câncer | |
| FI117888B (fi) | Mikrojauhettua nebivololia sisältäviä koostumuksia | |
| CN107530348B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| RU2323003C2 (ru) | Пероральные фармацевтические формы жидких лекарственных средств, имеющих улучшенную биодоступность | |
| BR112020024107A2 (pt) | combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos | |
| WO2007061415A1 (en) | Pharmaceutical compositions of telmisartan | |
| FI94925B (fi) | Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi | |
| US6833478B2 (en) | N,N-dinitramide salts as solubilizing agents for biologically active agents | |
| CO5060477A1 (es) | Forma de dosificacion de nefazodona | |
| CA2650698A1 (en) | Copolyvidone-containing preparation | |
| KR20110115592A (ko) | 피리도피리미디논의 고체 경구 제제 | |
| KR20040074052A (ko) | 증가된 용해도를 갖는 플라바노리그난 제제 | |
| US20070116759A1 (en) | Pharmaceutical compositions of telmisartan | |
| RU2662562C2 (ru) | Композиция в форме таблеток, содержащая гидрохлорид цинакалцета | |
| ES2288117A1 (es) | Composicion farmaceutica solida de gabapentina. | |
| RU2674978C2 (ru) | Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида | |
| US20210169856A1 (en) | Formulations comprising dopamine-b-hydroxylase inhibitors and methods for their preparation | |
| KR100422418B1 (ko) | 불용성 약물의 서방형 제제의 제조방법 | |
| WO2019008426A1 (en) | NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME | |
| WO2013124818A1 (en) | Taste masked dispersible tablets | |
| CA2520813A1 (en) | Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists | |
| JP7432501B2 (ja) | チモキノン含有組成物の調製法 | |
| KR100546047B1 (ko) | 디히드로피리딘계 화합물의 서방출성 제제 및 그 제조방법 | |
| ES2875405T3 (es) | Composición farmacéutica que comprende darunavir y método para su preparación | |
| EP3027177B1 (en) | A modified-release oral pharmaceutical formulation containing gliclazide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |